Skip to main content
Breaking News
Feature Story

Viral crossroads

BioCentury is providing in-depth analysis of the sudden impact of social media on difficult medical and ethical decisions surrounding compassionate access to experimental medicines. See the story from a multitude of angles in our continuing coverage.

Full Article

    Unlocking cancer data

    With upfront buy-in from executive leadership in industry, academia and non-profits, Project Data Sphere for cancer could overcome challenges that have slowed other data-sharing efforts.

  • Blazing a path in data sharing

    The cancer data-sharing group Project Data Sphere met with the Critical Path Institute to learn from the institute's data-sharing initiatives for neurodegenerative diseases.


    Family resemblance

    Data reported so far for the most advanced PCSK9 inhibitors look similar, but trials in the LDL-lowering indications where the products will see the earliest uptake are still to come.


    Quantum: Silicon speed

    Quantum Biosystems has joined the single-molecule sequencing race with a solid-state system that could offer improved development timelines over nanopore technologies.


    Reasons Unknown

    Whatever caused Kenneth Moch to depart Chimerix as president and CEO, it wasn't stock performance.

  • Guest Commentary: Reducing the Burden

    In a Guest Commentary, two capital market veterans argue it is time to modify SEC disclosure rules that are not only a burden to young public biotechs, but do little to actually help investors.

  • Lean VC Profile

    Early backing from strategic investors and a string of deals like a new Celgene partnership have given Forma a free hand to build its drug discovery engine without leaning on VCs.

  • Ebb & Flow

    Deerfield's new crossover mandate. Nucana's B may be plenty. SkyPharma's debt riddance. Spinifex's U.S. beachhead. Also: Gilead; Biogen; Agios; Idenix; Puma; Adamas; Celladon, et al.

Today's Biotech & Pharma News

Compassionate Access


    Contaminating cancer genomes

    Two European teams have pinpointed a DNA-protective enzyme as a chemically tractable target whose inhibition kills cancer cells by accelerating DNA damage. Both groups have identified small molecule inhibitors of the enzyme and are looking to partner with industry.


    Translational tidbits

    AstraZeneca had a busy March, announcing five new public-private partnerships and launching its Open Innovation website to list additional partnership opportunities.

  • Expanding into new (bromo)domains

    The Neomed Institute has begun development of its first cancer therapeutic, a BRD4 inhibitor from Epigenetix that the not-for-profit organization thinks could have a selectivity advantage over competing molecules.


    Unfolding triple-negative breast cancer

    A team from Weill Cornell Medical College has found a unifying feature of triple-negative breast cancers -- overactivation of the transcription factor X-box binding protein 1. Blocking expression of the target decreases tumor formation and relapse in mice, but more druggable targets upstream of it might be better suited for further development.


    This Week in Therapeutics

    Inhibiting IL-17A or IL-23 to alleviate periodontitis; antagonizing KCNA3 to treat asthma; activating CD31 signaling to counter autoimmune and inflammatory conditions; and more...


    This Week in Techniques

    Isoacyl dipeptides to increase insulin yield from chemical synthesis; binary nylon-3 copolymers containing cationic and hydrophobic subunits for antimicrobial activity; markers of distinct SHH-driven medulloblastomas; and more...

Subscribe Now
Free Trial

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.